Altimmune (NASDAQ:ALT) Earns Buy Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 183.02% from the company’s previous close.

Several other research firms have also commented on ALT. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Stifel Nicolaus started coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Trading Down 4.9 %

ALT opened at $4.24 on Thursday. The stock has a market capitalization of $326.54 million, a P/E ratio of -2.74 and a beta of 0.91. The stock has a 50-day moving average price of $6.01 and a 200-day moving average price of $6.96. Altimmune has a 12-month low of $4.13 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, equities research analysts predict that Altimmune will post -1.35 EPS for the current year.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $52,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP lifted its stake in Altimmune by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 205,233 shares of the company’s stock worth $1,480,000 after acquiring an additional 8,001 shares during the period. Sunbelt Securities Inc. raised its holdings in Altimmune by 356.8% in the 4th quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after purchasing an additional 8,470 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Altimmune by 16.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,392 shares of the company’s stock worth $666,000 after purchasing an additional 13,126 shares during the period. Two Sigma Investments LP boosted its stake in shares of Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after purchasing an additional 151,001 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its position in shares of Altimmune by 1.3% during the fourth quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock valued at $1,137,000 after buying an additional 1,964 shares during the period. 78.05% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.